Atropine 0.01% eye drops slow myopia progression: a systematic review and Meta-analysis |
| |
Authors: | Ying Zhao Kai Feng Rui-Bao Liu Jin-Hua Pan Lai-Lin Zhang Zhu-Ping Xu and Xue-Jing Lu |
| |
Institution: | Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China,Beijing University of Chinese Medicine, Beijing 100029, China,Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China,Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China,Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China,West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China and Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China |
| |
Abstract: | AIM: To evaluate the effects of atropine 0.01% on slowing myopia progression.
METHODS: We searched for relevant studies in the Cochrane Library, PubMed, Embase, Ovid, CBM, CNKI, VIP and Wan Fang Data in Chinese. A supplementary search was conducted in OpenGrey (System for Information on Grey Literature in Europe), the ISRCTN registry, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) from the dates of inception to June 30, 2018.
RESULTS: Seven randomized controlled trials (RCTs) with a total of 1079 subjects were included (505 in the atropine 0.01% group and 574 in the control group). The results showed that the atropine 0.01% group exhibited significantly greater control of axial growth than the control group MD=-0.12, 95%CI (-0.19, -0.06)]. There was also a statistically significant difference between the atropine 0.01% and control groups in the changes in axial length MD=-0.14, 95%CI (-0.25, -0.03)], but the quality of evidence was low. There were no significant differences between the atropine 0.01% and control groups in the overall effect with respect to diopter value, change in diopter, distance vision and intraocular pressure MD=0.08, 95%CI (-0.27, 0.42); MD=0.09, 95%CI (-0.17, 0.36); MD= -0.01, 95%CI (-0.02, 0.00); MD=0.08, 95%CI (-0.56,0.40)]. The sensitivity analysis showed that the conclusion of the Meta-analysis is relatively stable. With respect to adverse events, there were significant differences between the atropine 0.01% and control groups OR=0.26, 95%CI (0.11, 0.61)].
CONCLUSION: Based on the available evidence, atropine 0.01% eye drops offer benefits in controlling axial growth and safety without causing significant differences in diopter values, distance vision and intraocular pressure. |
| |
Keywords: | atropine 0 01% eye drops myopia systematic review Meta-analysis |
|
| 点击此处可从《国际眼科杂志(英文版)》浏览原始摘要信息 |
| 点击此处可从《国际眼科杂志(英文版)》下载免费的PDF全文 |
|